Anti-TNF

ApprovedSmall molecule

Johnson & Johnson

Anti-TNF is one of 201 small molecule programs targeting Juvenile Idiopathic Arthritis. It is currently in Approved.

Indications

Total Trials

Active Trials

200

Competitors

Pipeline

Status by Indication[3][1]

Indication

Juvenile Idiopathic ArthritisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

PsoriasisActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

DementiaActive, not recruiting

Skin DiseaseActive, not recruiting

Juvenile Idiopathic ArthritisApproved

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

PsoriasisPreclinical

Active, not recruiting

Ankylosing SpondylitisPhase 3

Active, not recruiting

DementiaPreclinical

Active, not recruiting

Skin DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Anti-TNF

Johnson & Johnson

Approved

1 2

Rituxan

Roche

Preclinical

61 3

Actemra

Cimzia

30 5

Arcoxia

Novartis

Preclinical

4 6

Actos

Takeda

Preclinical

2 7

Celexa

AbbVie

Preclinical

1 8

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 9

Cataflam

Rituxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Recruiting

Skin Disease

NCT03358693

Clinical

Trials by Indication[1]

Crohn's Disease2 trials

Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease

Completed·UUniversity of Maryland, Baltimore··NCT02619552·50 enrolled

Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection

Withdrawn·UUniversity Hospital, Lille·N/A·NCT02872506

Skin Disease1 trial

Molecular Signatures in Inflammatory Skin Disease

Recruiting·PProf. Dr. Stephan Weidinger··NCT03358693·300 enrolled

Juvenile Idiopathic Arthritis1 trial

23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy

Completed·UUniversity of Sao Paulo·Phase 4·NCT02196480·27 enrolled

Dementia1 trial

A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT04571697·34,647 enrolled

Ankylosing Spondylitis1 trial

Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes

Completed·UUniversity Hospital, Bordeaux·Phase 3·NCT02469753·188 enrolled

3 more indications

Rheumatoid Arthritis1 trial

The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Withdrawn·AAbu Dhabi Stem Cells Center·Phase 3·NCT05379322

Psoriasis1 trial

National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

Completed·UUniversity of Rochester··NCT01123265·22 enrolled

Biomarkers1 trial

Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF

Unknown status·HHospital Universitari Vall d'Hebron Research Institute··NCT02804204·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Anti-TNF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-TNF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-TNF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Johnson & Johnson

Anti-TNF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Crohn's Disease2 trials

Skin Disease1 trial

Juvenile Idiopathic Arthritis1 trial

Dementia1 trial

Ankylosing Spondylitis1 trial

Rheumatoid Arthritis1 trial

Psoriasis1 trial

Biomarkers1 trial

References

Drug Info

Quick Facts

Related News